Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Nov, 2016 | Pages:
1298 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Type 2 Diabetes - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Type 2 Diabetes - Pipeline Review, H2 2016, provides an overview of the Type 2 Diabetes (Metabolic Disorders) pipeline landscape. Type 2 diabetes is a chronic condition and is the most common form of diabetes. High levels of glucose are a characteristic feature. The body might become resistant to insulin or may not produce enough amounts. Due to abnormal insulin functioning, glucose is concentrated in the blood leading to elevated levels and hence causing type 2 diabetes. Symptoms include fatigue, weight issues, vision deficits and various other effects. Risk factors include family history, age, obesity, physical inactivity and high blood pressure. This condition is handled by lifestyle alterations and regular medications. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Type 2 Diabetes - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Type 2 Diabetes (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Type 2 Diabetes (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Type 2 Diabetes and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 18, 25, 71, 54, 6, 252, 85 and 7 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 66 and 20 molecules, respectively.Type 2 Diabetes. Type 2 Diabetes (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Type 2 Diabetes (Metabolic Disorders). - The pipeline guide reviews pipeline therapeutics for Type 2 Diabetes (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Type 2 Diabetes (Metabolic Disorders) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Type 2 Diabetes (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Type 2 Diabetes (Metabolic Disorders) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Type 2 Diabetes (Metabolic Disorders). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Type 2 Diabetes (Metabolic Disorders) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents Table of Contents 2 Introduction 12 Type 2 Diabetes Overview 13 Therapeutics Development 14 Type 2 Diabetes - Therapeutics under Development by Companies 16 Type 2 Diabetes - Therapeutics under Investigation by Universities/Institutes 36 Type 2 Diabetes - Pipeline Products Glance 40 Type 2 Diabetes - Products under Development by Companies 44 Type 2 Diabetes - Products under Investigation by Universities/Institutes 78 Type 2 Diabetes - Companies Involved in Therapeutics Development 84 Type 2 Diabetes - Therapeutics Assessment 313 Drug Profiles 368 Type 2 Diabetes - Dormant Projects 1156 Type 2 Diabetes - Discontinued Products 1204 Type 2 Diabetes - Product Development Milestones 1223 Appendix 1236
List of Tables Number of Products under Development for Type 2 Diabetes, H2 2016 75 Number of Products under Development for Type 2 Diabetes - Comparative Analysis, H2 2016 76 Number of Products under Development by Companies, H2 2016 78 Number of Products under Development by Companies, H2 2016 (Contd..1) 79 Number of Products under Development by Companies, H2 2016 (Contd..2) 80 Number of Products under Development by Companies, H2 2016 (Contd..3) 81 Number of Products under Development by Companies, H2 2016 (Contd..4) 82 Number of Products under Development by Companies, H2 2016 (Contd..5) 83 Number of Products under Development by Companies, H2 2016 (Contd..6) 84 Number of Products under Development by Companies, H2 2016 (Contd..7) 85 Number of Products under Development by Companies, H2 2016 (Contd..8) 86 Number of Products under Development by Companies, H2 2016 (Contd..9) 87 Number of Products under Development by Companies, H2 2016 (Contd..10) 88 Number of Products under Development by Companies, H2 2016 (Contd..11) 89 Number of Products under Development by Companies, H2 2016 (Contd..12) 90 Number of Products under Development by Companies, H2 2016 (Contd..13) 91 Number of Products under Development by Companies, H2 2016 (Contd..14) 92 Number of Products under Development by Companies, H2 2016 (Contd..15) 93 Number of Products under Development by Companies, H2 2016 (Contd..16) 94 Number of Products under Development by Companies, H2 2016 (Contd..17) 95 Number of Products under Development by Companies, H2 2016 (Contd..18) 96 Number of Products under Investigation by Universities/Institutes, H2 2016 97 Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 98 Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 99 Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..3) 100 Comparative Analysis by Late Stage Development, H2 2016 101 Comparative Analysis by Clinical Stage Development, H2 2016 102 Comparative Analysis by Early Stage Development, H2 2016 103 Comparative Analysis by Unknown Stage Development, H2 2016 104 Products under Development by Companies, H2 2016 105 Products under Development by Companies, H2 2016 (Contd..1) 106 Products under Development by Companies, H2 2016 (Contd..2) 107 Products under Development by Companies, H2 2016 (Contd..3) 108 Products under Development by Companies, H2 2016 (Contd..4) 109 Products under Development by Companies, H2 2016 (Contd..5) 110 Products under Development by Companies, H2 2016 (Contd..6) 111 Products under Development by Companies, H2 2016 (Contd..7) 112 Products under Development by Companies, H2 2016 (Contd..8) 113 Products under Development by Companies, H2 2016 (Contd..9) 114 Products under Development by Companies, H2 2016 (Contd..10) 115 Products under Development by Companies, H2 2016 (Contd..11) 116 Products under Development by Companies, H2 2016 (Contd..12) 117 Products under Development by Companies, H2 2016 (Contd..13) 118 Products under Development by Companies, H2 2016 (Contd..14) 119 Products under Development by Companies, H2 2016 (Contd..15) 120 Products under Development by Companies, H2 2016 (Contd..16) 121 Products under Development by Companies, H2 2016 (Contd..17) 122 Products under Development by Companies, H2 2016 (Contd..18) 123 Products under Development by Companies, H2 2016 (Contd..19) 124 Products under Development by Companies, H2 2016 (Contd..20) 125 Products under Development by Companies, H2 2016 (Contd..21) 126 Products under Development by Companies, H2 2016 (Contd..22) 127 Products under Development by Companies, H2 2016 (Contd..23) 128 Products under Development by Companies, H2 2016 (Contd..24) 129 Products under Development by Companies, H2 2016 (Contd..25) 130 Products under Development by Companies, H2 2016 (Contd..26) 131 Products under Development by Companies, H2 2016 (Contd..27) 132 Products under Development by Companies, H2 2016 (Contd..28) 133 Products under Development by Companies, H2 2016 (Contd..29) 134 Products under Development by Companies, H2 2016 (Contd..30) 135 Products under Development by Companies, H2 2016 (Contd..31) 136 Products under Development by Companies, H2 2016 (Contd..32) 137 Products under Development by Companies, H2 2016 (Contd..33) 138 Products under Investigation by Universities/Institutes, H2 2016 139 Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 140 Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 141 Products under Investigation by Universities/Institutes, H2 2016 (Contd..3) 142 Products under Investigation by Universities/Institutes, H2 2016 (Contd..4) 143 Products under Investigation by Universities/Institutes, H2 2016 (Contd..5) 144 Type 2 Diabetes - Pipeline by Addex Therapeutics Ltd, H2 2016 145 Type 2 Diabetes - Pipeline by Adocia, H2 2016 146 Type 2 Diabetes - Pipeline by Advinus Therapeutics Ltd, H2 2016 147 Type 2 Diabetes - Pipeline by Aegis Therapeutics, LLC, H2 2016 148 Type 2 Diabetes - Pipeline by AFFiRiS AG, H2 2016 149 Type 2 Diabetes - Pipeline by Alize Pharma SAS, H2 2016 150 Type 2 Diabetes - Pipeline by AlphaMab Co., Ltd, H2 2016 151 Type 2 Diabetes - Pipeline by Alteogen Inc., H2 2016 152 Type 2 Diabetes - Pipeline by Amarantus Bioscience Holdings, Inc., H2 2016 153 Type 2 Diabetes - Pipeline by Ambrx, Inc., H2 2016 154 Type 2 Diabetes - Pipeline by Amgen Inc., H2 2016 155 Type 2 Diabetes - Pipeline by Anchor Therapeutics, Inc., H2 2016 156 Type 2 Diabetes - Pipeline by AntriaBio, Inc., H2 2016 157 Type 2 Diabetes - Pipeline by Aphios Corporation, H2 2016 158 Type 2 Diabetes - Pipeline by APT Therapeutics, Inc., H2 2016 159 Type 2 Diabetes - Pipeline by Araim Pharmaceuticals, Inc., H2 2016 160 Type 2 Diabetes - Pipeline by Arisaph Pharmaceuticals, Inc., H2 2016 161 Type 2 Diabetes - Pipeline by ArisGen SA, H2 2016 162 Type 2 Diabetes - Pipeline by Artery Therapeutics, Inc., H2 2016 163 Type 2 Diabetes - Pipeline by Astellas Pharma Inc., H2 2016 164 Type 2 Diabetes - Pipeline by AstraZeneca Plc, H2 2016 165 Type 2 Diabetes - Pipeline by Aus Bio Ltd, H2 2016 166 Type 2 Diabetes - Pipeline by Bayer AG, H2 2016 167 Type 2 Diabetes - Pipeline by Beta-Cell NV, H2 2016 168 Type 2 Diabetes - Pipeline by Betagenon AB, H2 2016 169 Type 2 Diabetes - Pipeline by Biocon Limited, H2 2016 170 Type 2 Diabetes - Pipeline by Biodel Inc., H2 2016 171 Type 2 Diabetes - Pipeline by Biogenomics Limited, H2 2016 172 Type 2 Diabetes - Pipeline by BioLingus AG, H2 2016 173 Type 2 Diabetes - Pipeline by BioRestorative Therapies, Inc., H2 2016 174 Type 2 Diabetes - Pipeline by BioTherapeutics Inc., H2 2016 175 Type 2 Diabetes - Pipeline by Biscayne Pharmaceuticals, Inc., H2 2016 176 Type 2 Diabetes - Pipeline by Boehringer Ingelheim GmbH, H2 2016 177 Type 2 Diabetes - Pipeline by Boston Therapeutics, Inc., H2 2016 178 Type 2 Diabetes - Pipeline by Braasch Biotech LLC, H2 2016 179 Type 2 Diabetes - Pipeline by Bristol-Myers Squibb Company, H2 2016 180 Type 2 Diabetes - Pipeline by C4X Discovery Holdings PLC, H2 2016 181 Type 2 Diabetes - Pipeline by Cadila Pharmaceuticals Limited, H2 2016 182 Type 2 Diabetes - Pipeline by Caldan Therapeutics Limited, H2 2016 183 Type 2 Diabetes - Pipeline by Cardax, Inc., H2 2016 184 Type 2 Diabetes - Pipeline by Carlina Technologies SAS, H2 2016 185 Type 2 Diabetes - Pipeline by Carmot Therapeutics Inc, H2 2016 186 Type 2 Diabetes - Pipeline by Celon Pharma Sp. z o.o., H2 2016 187 Type 2 Diabetes - Pipeline by Chipscreen Biosciences Ltd, H2 2016 188 Type 2 Diabetes - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2016 189 Type 2 Diabetes - Pipeline by CJ HealthCare Corp., H2 2016 190 Type 2 Diabetes - Pipeline by CohBar, Inc., H2 2016 191 Type 2 Diabetes - Pipeline by ConjuChem, LLC, H2 2016 192 Type 2 Diabetes - Pipeline by Connexios Life Sciences Pvt. Ltd., H2 2016 193 Type 2 Diabetes - Pipeline by Corium International, Inc., H2 2016 194 Type 2 Diabetes - Pipeline by CureDM, Inc., H2 2016 195 Type 2 Diabetes - Pipeline by CymaBay Therapeutics, Inc., H2 2016 196 Type 2 Diabetes - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2016 197 Type 2 Diabetes - Pipeline by Daiichi Sankyo Company, Limited, H2 2016 198 Type 2 Diabetes - Pipeline by Dance Biopharm Inc., H2 2016 199 Type 2 Diabetes - Pipeline by Delpor, Inc., H2 2016 200 Type 2 Diabetes - Pipeline by Diabetica Limited, H2 2016 201 Type 2 Diabetes - Pipeline by Diabetology (Products) Ltd, H2 2016 202 Type 2 Diabetes - Pipeline by DiaMedica Inc., H2 2016 203 Type 2 Diabetes - Pipeline by Diamyd Medical AB, H2 2016 204 Type 2 Diabetes - Pipeline by Diasome Pharmaceuticals, Inc., H2 2016 205 Type 2 Diabetes - Pipeline by DiscoveryBiomed, Inc., H2 2016 206 Type 2 Diabetes - Pipeline by DNJ Pharma, Inc., H2 2016 207 Type 2 Diabetes - Pipeline by Dong-A Socio Holdings Co. Ltd., H2 2016 208 Type 2 Diabetes - Pipeline by Elcelyx Therapeutics Inc, H2 2016 209 Type 2 Diabetes - Pipeline by Eli Lilly and Company, H2 2016 210 Type 2 Diabetes - Pipeline by enGene, Inc, H2 2016 211 Type 2 Diabetes - Pipeline by Enzo Biochem, Inc., H2 2016 212 Type 2 Diabetes - Pipeline by Epichem Pty Ltd, H2 2016 213 Type 2 Diabetes - Pipeline by Esperion Therapeutics, Inc., H2 2016 214 Type 2 Diabetes - Pipeline by Eternygen GmbH, H2 2016 215 Type 2 Diabetes - Pipeline by Evotec AG, H2 2016 216 Type 2 Diabetes - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 217 Type 2 Diabetes - Pipeline by FibroStatin SL, H2 2016 218 Type 2 Diabetes - Pipeline by Flamel Technologies S.A., H2 2016 219 Type 2 Diabetes - Pipeline by Generex Biotechnology Corporation, H2 2016 220 Type 2 Diabetes - Pipeline by Genfit SA, H2 2016 221 Type 2 Diabetes - Pipeline by Genovate Biotechnology Co., LTD., H2 2016 222 Type 2 Diabetes - Pipeline by Gero Corp, H2 2016 223 Type 2 Diabetes - Pipeline by Geropharm, H2 2016 224 Type 2 Diabetes - Pipeline by Gilead Sciences, Inc., H2 2016 225 Type 2 Diabetes - Pipeline by GlaxoSmithKline Plc, H2 2016 226 Type 2 Diabetes - Pipeline by Glide Pharmaceutical Technologies Limited, H2 2016 227 Type 2 Diabetes - Pipeline by Glucox Biotech AB, H2 2016 228 Type 2 Diabetes - Pipeline by GW Pharmaceuticals Plc, H2 2016 229 Type 2 Diabetes - Pipeline by Hadasit Medical Research Services & Development Ltd, H2 2016 230 Type 2 Diabetes - Pipeline by HanAll Biopharma Co., Ltd., H2 2016 231 Type 2 Diabetes - Pipeline by Handok Inc., H2 2016 232 Type 2 Diabetes - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2016 233 Type 2 Diabetes - Pipeline by HEC Pharm Co., Ltd., H2 2016 234 Type 2 Diabetes - Pipeline by Heptares Therapeutics Limited, H2 2016 235 Type 2 Diabetes - Pipeline by HitGen LTD, H2 2016 236 Type 2 Diabetes - Pipeline by Hua Medicine (Shanghai) Ltd., H2 2016 237 Type 2 Diabetes - Pipeline by Hyundai Pharmaceutical Co., Ltd., H2 2016 238 Type 2 Diabetes - Pipeline by Immuron Limited, H2 2016 239 Type 2 Diabetes - Pipeline by Innopharmax Inc., H2 2016 240 Type 2 Diabetes - Pipeline by Innovative Targeting Solutions Inc, H2 2016 241 Type 2 Diabetes - Pipeline by Intarcia Therapeutics, Inc., H2 2016 242 Type 2 Diabetes - Pipeline by Intas Pharmaceuticals Ltd., H2 2016 243 Type 2 Diabetes - Pipeline by Integral Molecular, Inc., H2 2016 244 Type 2 Diabetes - Pipeline by Intercept Pharmaceuticals, Inc., H2 2016 245 Type 2 Diabetes - Pipeline by Intrexon Corporation, H2 2016 246 Type 2 Diabetes - Pipeline by Ionis Pharmaceuticals, Inc., H2 2016 247 Type 2 Diabetes - Pipeline by Ironwood Pharmaceuticals, Inc., H2 2016 248 Type 2 Diabetes - Pipeline by Islet Sciences, Inc., H2 2016 249 Type 2 Diabetes - Pipeline by Ixchel Pharma, LLC, H2 2016 250 Type 2 Diabetes - Pipeline by Japan Tobacco Inc., H2 2016 251 Type 2 Diabetes - Pipeline by Jeil Pharmaceutical Co., Ltd., H2 2016 252 Type 2 Diabetes - Pipeline by Jenrin Discovery, Inc., H2 2016 253 Type 2 Diabetes - Pipeline by JHL Biotech, Inc., H2 2016 254 Type 2 Diabetes - Pipeline by Jiangsu Hansoh Pharmaceutical Co., Ltd., H2 2016 255 Type 2 Diabetes - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2016 256 Type 2 Diabetes - Pipeline by Johnson & Johnson, H2 2016 257 Type 2 Diabetes - Pipeline by Kadimastem Ltd., H2 2016 258 Type 2 Diabetes - Pipeline by Kadmon Corporation, LLC, H2 2016 259 Type 2 Diabetes - Pipeline by Kareus Therapeutics, SA, H2 2016 260 Type 2 Diabetes - Pipeline by Kissei Pharmaceutical Co., Ltd., H2 2016 261 Type 2 Diabetes - Pipeline by Lead Discovery Center GmbH, H2 2016 262 Type 2 Diabetes - Pipeline by Leading BioSciences, Inc., H2 2016 263 Type 2 Diabetes - Pipeline by Lexicon Pharmaceuticals, Inc., H2 2016 264 Type 2 Diabetes - Pipeline by LG Life Science LTD., H2 2016 265 Type 2 Diabetes - Pipeline by Ligand Pharmaceuticals, Inc., H2 2016 266 Type 2 Diabetes - Pipeline by LipimetiX Development Inc, H2 2016 267 Type 2 Diabetes - Pipeline by Lonestar Heart, Inc., H2 2016 268 Type 2 Diabetes - Pipeline by Longevity Biotech, Inc, H2 2016 269 Type 2 Diabetes - Pipeline by Magnus Life Ltd, H2 2016 270 Type 2 Diabetes - Pipeline by Medesis Pharma S.A., H2 2016 271 Type 2 Diabetes - Pipeline by Medestea Research & Production S.p.A., H2 2016 272 Type 2 Diabetes - Pipeline by MedImmune LLC, H2 2016 273 Type 2 Diabetes - Pipeline by Mellitech SAS, H2 2016 274 Type 2 Diabetes - Pipeline by Merck & Co., Inc., H2 2016 275 Type 2 Diabetes - Pipeline by Mesoblast Limited, H2 2016 276 Type 2 Diabetes - Pipeline by Metabolic Solutions Development Company, LLC, H2 2016 277 Type 2 Diabetes - Pipeline by Metabolys SAS, H2 2016 278 Type 2 Diabetes - Pipeline by Metacrine, Inc., H2 2016 279 Type 2 Diabetes - Pipeline by MicroBiome Therapeutics LLC, H2 2016 280 Type 2 Diabetes - Pipeline by MidaSol Therapeutics LP, H2 2016 281 Type 2 Diabetes - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2016 282 Type 2 Diabetes - Pipeline by Moderna Therapeutics Inc, H2 2016 283 Type 2 Diabetes - Pipeline by Naia Limited, H2 2016 284 Type 2 Diabetes - Pipeline by Neurimmune Holding AG, H2 2016 285 Type 2 Diabetes - Pipeline by Neurocrine Biosciences, Inc., H2 2016 286 Type 2 Diabetes - Pipeline by NGM Biopharmaceuticals, Inc., H2 2016 287 Type 2 Diabetes - Pipeline by Nordic Bioscience A/S, H2 2016 288 Type 2 Diabetes - Pipeline by Novapeutics, LLC, H2 2016 289 Type 2 Diabetes - Pipeline by Novartis AG, H2 2016 290 Type 2 Diabetes - Pipeline by NovaTarg Therapeutics, Inc, H2 2016 291 Type 2 Diabetes - Pipeline by Novo Nordisk A/S, H2 2016 292 Type 2 Diabetes - Pipeline by Noxxon Pharma AG, H2 2016 293 Type 2 Diabetes - Pipeline by Ogeda SA, H2 2016 294 Type 2 Diabetes - Pipeline by Omeros Corporation, H2 2016 295 Type 2 Diabetes - Pipeline by OPKO Biologics Ltd, H2 2016 296 Type 2 Diabetes - Pipeline by OPKO Health, Inc., H2 2016 297 Type 2 Diabetes - Pipeline by Oramed Pharmaceuticals, Inc., H2 2016 298 Type 2 Diabetes - Pipeline by Orbis Biosciences Inc, H2 2016 299 Type 2 Diabetes - Pipeline by Panacea Biotec Limited, H2 2016 300 Type 2 Diabetes - Pipeline by Paras Biopharmaceuticals Finland Oy, H2 2016 301 Type 2 Diabetes - Pipeline by Peptron, Inc., H2 2016 302 Type 2 Diabetes - Pipeline by Pfizer Inc., H2 2016 303 Type 2 Diabetes - Pipeline by PharmaCyte Biotech, Inc., H2 2016 304 Type 2 Diabetes - Pipeline by PharmaIN Corporation, H2 2016 305 Type 2 Diabetes - Pipeline by PhaseBio Pharmaceuticals, Inc., H2 2016 306 Type 2 Diabetes - Pipeline by Pila Pharma AB, H2 2016 307 Type 2 Diabetes - Pipeline by Pivot Pharmaceuticals Inc, H2 2016 308 Type 2 Diabetes - Pipeline by Poxel SA, H2 2016 309 Type 2 Diabetes - Pipeline by Prometheon Pharma, LLC, H2 2016 310 Type 2 Diabetes - Pipeline by ProMetic Life Sciences Inc., H2 2016 311 Type 2 Diabetes - Pipeline by Purzer Pharmaceutical Co., Ltd., H2 2016 312 Type 2 Diabetes - Pipeline by Reata Pharmaceuticals, Inc., H2 2016 313 Type 2 Diabetes - Pipeline by ReCyte Therapeutics, Inc., H2 2016 314 Type 2 Diabetes - Pipeline by Red Glead Discovery AB, H2 2016 315 Type 2 Diabetes - Pipeline by RegenMedTX, LLC, H2 2016 316 Type 2 Diabetes - Pipeline by reMYND NV, H2 2016 317 Type 2 Diabetes - Pipeline by Renova Therapeutics Inc, H2 2016 318 Type 2 Diabetes - Pipeline by Saniona AB, H2 2016 319 Type 2 Diabetes - Pipeline by Sanofi, H2 2016 320 Type 2 Diabetes - Pipeline by Sanwa Kagaku Kenkyusho Co., Ltd., H2 2016 321 Type 2 Diabetes - Pipeline by SATT Conectus Alsace SAS, H2 2016 322 Type 2 Diabetes - Pipeline by SBI Pharmaceuticals Co., Ltd., H2 2016 323 Type 2 Diabetes - Pipeline by Selvita S.A., H2 2016 324
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
